Compare BC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BC | PRAX |
|---|---|---|
| Founded | 1845 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.0B |
| IPO Year | N/A | 2020 |
| Metric | BC | PRAX |
|---|---|---|
| Price | $74.53 | $277.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $69.08 | ★ $304.43 |
| AVG Volume (30 Days) | 868.3K | ★ 1.1M |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,183,900,000.00 | $7,463,000.00 |
| Revenue This Year | $2.88 | N/A |
| Revenue Next Year | $5.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $41.00 | $26.70 |
| 52 Week High | $76.36 | $278.44 |
| Indicator | BC | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 67.59 | 73.04 |
| Support Level | $73.57 | $251.00 |
| Resistance Level | $75.55 | $282.99 |
| Average True Range (ATR) | 1.97 | 16.01 |
| MACD | 0.66 | 5.56 |
| Stochastic Oscillator | 87.44 | 94.10 |
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns 440 Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.